Eravacycline, an antibacterial drug, repurposed for pancreatic cancer therapy: insights from a molecular-based deep learning model.

Journal: Briefings in bioinformatics
PMID: 38647152

Abstract

BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) remains a serious threat to health, with limited effective therapeutic options, especially due to advanced stage at diagnosis and its inherent resistance to chemotherapy, making it one of the leading causes of cancer-related deaths worldwide. The lack of clear treatment directions underscores the urgent need for innovative approaches to address and manage this deadly condition. In this research, we repurpose drugs with potential anti-cancer activity using machine learning (ML).

Authors

  • Adi Jabarin
    Department of Clinical Biochemistry and Pharmacology, Ben-Gurion University of the Negev (BGU), P.O.B. 653, Beer-Sheva 8410501, Israel.
  • Guy Shtar
    Department of Software and Information Systems Engineering, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
  • Valeria Feinshtein
    Department of Clinical Biochemistry and Pharmacology, Ben-Gurion University of the Negev (BGU), P.O.B. 653, Beer-Sheva 8410501, Israel.
  • Eyal Mazuz
    Department of Software and Information Systems Engineering, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
  • Bracha Shapira
    Department of Software and Information Systems Engineering, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
  • Shimon Ben-Shabat
    Department of Clinical Biochemistry and Pharmacology, Ben-Gurion University of the Negev (BGU), P.O.B. 653, Beer-Sheva 8410501, Israel.
  • Lior Rokach

Keywords

External Resources

Popular Topics
Recent Journals